CoChat

A Comprehensive Strategy to Discover Inhibitors of the Translesion Synthesis DNA Polymerase κ

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Human DNA polymerase kappa (pol κ) is a translesion synthesis (TLS) polymerase that catalyzes TLS past various minor groove lesions including N(2)-dG linked acrolein- and polycyclic aromatic hydrocarbon-derived adducts, as well as N(2)-dG DNA-DNA interstrand cross-links introduced by the chemotherapeutic agent mitomycin C. It also processes ultraviolet light-induced DNA lesions. Since pol κ TLS activity can reduce the cellular toxicity of chemotherapeutic agents and since gliomas overexpress pol κ, small molecule library screens targeting pol κ were conducted to initiate the first step in the development of new adjunct cancer therapeutics. A high-throughput, fluorescence-based DNA strand displacement assay was utilized to screen ∼16,000 bioactive compounds, and the 60 top hits were validated by primer extension assays using non-damaged DNAs. Candesartan cilexetil, manoalide, and MK-886 were selected as proof-of-principle compounds and further characterized for their specificity toward pol κ by primer extension assays using DNAs containing a site-specific acrolein-derived, ring-opened reduced form of γ-HOPdG. Furthermore, candesartan cilexetil could enhance ultraviolet light-induced cytotoxicity in xeroderma pigmentosum variant cells, suggesting its inhibitory effect against intracellular pol κ. In summary, this investigation represents the first high-throughput screening designed to identify inhibitors of pol κ, with the characterization of biochemical and biologically relevant endpoints as a consequence of pol κ inhibition. These approaches lay the foundation for the future discovery of compounds that can be applied to combination chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0045032

Cites

Statistics

Figures

Figure 1 Principle of the fluorescence-based polymerase-catalyzed strand displacement assay. Pol κ-catalyzed DNA synthesis displaces TAMRA-labeled reporter strand. This process relieves the quenching effect of BHQ-2, leading to an increase in fluorescence signals.
Figure 1 Principle of the fluorescence-based polymerase-catalyzed strand displacement assay. Pol κ-catalyzed DNA synthesis displaces TAMRA-labeled reporter strand. This process relieves the quenching effect of BHQ-2, leading to an increase in fluorescence signals.CC0 · PubMed Central
Figure 2 Summary of results from qHTS. (A) Excellent Z′ factor of >0.75 was maintained throughout the screen. (B) Concentration-response curves of top hits derived from the screen.
Figure 2 Summary of results from qHTS. (A) Excellent Z′ factor of >0.75 was maintained throughout the screen. (B) Concentration-response curves of top hits derived from the screen.CC0 · PubMed Central
Figure 3 Dose-response activities of (A) candesartan cilexetil, (B) manoalide, and (C) MK-886 on non-damaged DNAs. Representative data from three independent experiments are shown. The gels shown on the top panel were used to generate dose-response curves shown on the bottom panel.
Figure 3 Dose-response activities of (A) candesartan cilexetil, (B) manoalide, and (C) MK-886 on non-damaged DNAs. Representative data from three independent experiments are shown. The gels shown on the top panel were used to generate dose-response curves shown on the bottom panel.CC0 · PubMed Central
Figure 4.Summary of IC50s of candesartan cilexetil, manoalide, and MK-886 from qHTS and primer extension assays. In primer extension assays, three independent experiments were carried out, and IC50s are shown as average ± standard error.
Figure 4.Summary of IC50s of candesartan cilexetil, manoalide, and MK-886 from qHTS and primer extension assays. In primer extension assays, three independent experiments were carried out, and IC50s are shown as average ± standard error.CC0 · PubMed Central
Figure 5 Dose-response activities of (A) candesartan cilexetil, (B) manoalide, and (C) MK-886 on adducted DNAs. Representative data from three independent experiments are shown. The gels shown on the top panel were used to generate dose-response curves shown on the bottom panel.
Figure 5 Dose-response activities of (A) candesartan cilexetil, (B) manoalide, and (C) MK-886 on adducted DNAs. Representative data from three independent experiments are shown. The gels shown on the top panel were used to generate dose-response curves shown on the bottom panel.CC0 · PubMed Central
Figure 6 Effect of candesartan cilexetil on UV-induced cytotoxicity using crystal violet assay. XP30RO cells were treated with 24 µM of candesartan cilexetil alone, UV alone at 1.5 J/m2, 4.5 J/m2, or 7.5 J/m2, or in combination. Percent survival was calculated by normalizing the data using the cell survival of untreated cells. The data were obtained from three independent experiments. Error bars represent standard deviations. I: candesartan cilexetil.
Figure 6 Effect of candesartan cilexetil on UV-induced cytotoxicity using crystal violet assay. XP30RO cells were treated with 24 µM of candesartan cilexetil alone, UV alone at 1.5 J/m2, 4.5 J/m2, or 7.5 J/m2, or in combination. Percent survival was calculated by normalizing the data using the cell survival of untreated cells. The data were obtained from three independent experiments. Error bars represent standard deviations. I: candesartan cilexetil.CC0 · PubMed Central
Figure 7 The non-DNA-intercalating property of candesartan cilexetil. Candesartan cilexetil or ethidium bromide was incubated with double-stranded DNA ladder, and the reaction products were run on 1% agarose gel and stained with ethidium bromide. Lane 1: No compound. Lane 2: 0.75 nmol of candesartan cilexetil was incubated with 1.5 nmol DNA. Lane 3: 3 nmol of candesartan cilexetil was incubated with 1.5 nmol DNA. Lane 4: 0.75 nmol of ethidium bromide was incubated with 1.5 nmol DNA. Lane 5: 3 nmol of ethidium bromide was incubated with 1.5 nmol DNA.
Figure 7 The non-DNA-intercalating property of candesartan cilexetil. Candesartan cilexetil or ethidium bromide was incubated with double-stranded DNA ladder, and the reaction products were run on 1% agarose gel and stained with ethidium bromide. Lane 1: No compound. Lane 2: 0.75 nmol of candesartan cilexetil was incubated with 1.5 nmol DNA. Lane 3: 3 nmol of candesartan cilexetil was incubated with 1.5 nmol DNA. Lane 4: 0.75 nmol of ethidium bromide was incubated with 1.5 nmol DNA. Lane 5: 3 nmol of ethidium bromide was incubated with 1.5 nmol DNA.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 42 · Cited by 35

Metadata

Authors
Yamanaka, K., Dorjsuren, D., Eoff, R. L., Egli, M., Maloney, D. J., Jadhav, A., Simeonov, A., & Lloyd, R. S.
Affiliations
  • Oregon Health & Science University (US)
  • National Institutes of Health (US)
  • University of Arkansas for Medical Sciences (US)
  • Vanderbilt University (US)
Corresponding author
Lloyd, R. Stephen
Venue
PLoS ONE
Published
2012-10-08
Volume
7
Issue
10
Pages
e45032
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2139146509
Cited by
35
References
42
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 5 · 2015: 2 · 2014: 2 · 2013: 4
FWCI
1.03
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, public-domain)
  • Europe PMC (PubMed Central) (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Vanderbilt University
  • University of California, San Francisco
  • National Institute of Mental Health (R03MH094179, R03 MH)
  • National Cancer Institute (R01CA106858, CA 106858, P01CA160032)
  • National Institute of General Medical Sciences (GM084460, T32GM071338, R00GM084460)
  • National Institute of Environmental Health Sciences (P01ES005355, ES 05355)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
Keywords
DNA polymerase kappa, translesion synthesis, polymerase inhibitors, small molecule screening, candesartan cilexetil, manoalide, MK-886, polycyclic aromatic hydrocarbons, mitomycin C, UV-induced DNA damage, glioma, combination chemotherapy
MeSH terms
Y-Family DNA Polymerases, Acrolein, Benzimidazoles, Biphenyl Compounds, Cell Line, Transformed, Cell Survival, Chlorobenzenes, Deoxyguanosine, DNA, DNA Damage, DNA-Directed DNA Polymerase, DNA Repair, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Enzyme Inhibitors, Humans, Indoles, Terpenes, Tetrazoles, Ultraviolet Rays, DNA Adducts, Nucleic Acid Synthesis Inhibitors, Small Molecule Libraries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Comprehensive Strategy to Discover Inhibitors of the Translesion Synthesis DNA Polymerase κ. https://app.cochat.ai/papers/10.1371/journal.pone.0045032
The paper
Yamanaka, K., Dorjsuren, D., Eoff, R. L., Egli, M., Maloney, D. J., Jadhav, A., Simeonov, A., & Lloyd, R. S. (2012). A Comprehensive Strategy to Discover Inhibitors of the Translesion Synthesis DNA Polymerase κ. PLoS ONE. https://doi.org/10.1371/journal.pone.0045032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.